Yingshu Life Raises Over RMB 100 Million in Series A Financing Led by Weigao Songyuan Fund and Followed by Longpan Investment

VCBeat has learned that Hangzhou Yingshu Life Technology Co., Ltd. (“Yingshu Life”) recently announced the completion of its Series A strategic financing round, exceeding RMB 100 million. The round was led by Weigao Songyuan Fund, with LapamCapital participating as a co-investor. Following this financing, the company will further expand its product portfolio of rigid endoscopes and single-use endoscopes, and accelerate the global layout of its sales channels.

Yingshu Life, established in 2021, is a medical device company engaged in the research and development, manufacturing, and sales of high-end medical endoscopy systems and related innovative products. The company’s product portfolio includes minimally invasive rigid endoscopy systems, optical rigid endoscopes, single-use electronic endoscopes, and high-value consumables associated with endoscopic procedures. Its solutions serve multiple clinical departments, including general surgery, urology, gynecology, gastroenterology, and pulmonology.

Yingshu Life Product Line

According to Frost & Sullivan, the global market size for medical endoscopes was $27 billion in 2024 and is projected to grow to $39.6 billion by 2030. The market size for medical endoscopes in China is expected to reach RMB 40 billion in 2025. Imports monopolize 90% of the market, with the disposable endoscope market growing at an annual rate of 70% and the fluorescence rigid endoscope market at 100%, both presenting significant opportunities for domestic substitution.

Yingshu is one of the few companies in China that has simultaneously mastered the core “chokehold” technologies for both rigid endoscopes and single-use flexible endoscopes. Leveraging this advantage, it continuously launches unique and scarce products and solutions, with multiple blockbuster products slated for global launch in the future.

There is substantial room for domestic substitution in the rigid endoscope market. The optical scope of rigid endoscope systems represents a core bottleneck constraining domestic development. YingShu is one of the few manufacturers globally with in-house R&D and production capabilities for high-end fluorescence rigid endoscopes, delivering world-leading performance. Meanwhile, YingShu’s 4K white-light endoscopes and host system stability have secured its position among the top tier in China.

Yingshu’s fluorescent endoscopes demonstrate superior performance in four key areas: anti-fogging, resistance to high temperature and pressure, 4K high resolution, and fluorescence enhancement, thereby breaking the technological monopoly held by German companies. Currently, Yingshu’s fluorescent laparoscopes have obtained EU CE marking and hold all three major certifications: CE, FDA, and NMPA.

Yingshu Fluorescence Laparoscope

The company also possesses a highly competitive disposable endoscopy platform. Core mechanical components (such as the bending section and insertion tube), laser welding, and CMOS optical modules are gradually achieving in-house production, enabling optimal cost efficiency. Yingshu’s independently developed disposable electronic bronchoscope and disposable electronic ureteroscope have already received regulatory approval for market launch in China, offering significant potential for future product expansion.

 Yingshu Disposable Electronic Ureteropyeloscope Catheter

Regarding this round of financing,Shuai Jinxiao, Founder of Yingshu LifeStatement: The global medical endoscopy industry offers substantial market opportunities, particularly in emerging niche segments such as fluorescence endoscopes and single-use electronic endoscopes. Chinese enterprises are poised to surpass overseas brands through technological innovation and cost optimization. Leveraging its inherent strengths, Inshu Life focuses on breakthroughs in core endoscopy-related technologies, meticulously refining product quality with patience and diligence, while deepening its expertise in areas of competitive advantage. We extend our sincere gratitude to Weigao Songyuan Fund and LapamCapital for their recognition of the company. With the support of both new and existing shareholders, we will leverage our technological and product advantages to actively expand into domestic and international markets, striving to become a competitive player in the endoscopy industry.

Xing Jianglong, General Manager of Weigao Songyuan FundStatement: China’s medical endoscopy sector is currently experiencing rapid development and a significant opportunity for domestic substitution. In the rigid endoscope market, we are optimistic about investment opportunities in the niche segment of high-end fluorescent optical scopes. The design and manufacturing of these scopes entail considerable technical challenges; superior optical solutions can reduce subsequent demands on image processing, withstand hundreds of cycles of high-temperature and high-pressure sterilization, and meet steadily growing global market demand. YingShu has mastered core underlying technologies, demonstrating exceptional performance in four key dimensions—anti-fogging, resistance to high temperature and pressure, 4K high resolution, and fluorescence intensity—thereby breaking the technological monopoly held by German companies. Meanwhile, YingShu boasts the most comprehensive platform for single-use electronic endoscopes, with the potential to achieve full localization of core components, thereby balancing performance advantages with cost efficiency. We are confident in the team’s extensive industry technical accumulation over many years and their strong execution capabilities. Through this strategic investment, both parties will fully leverage their respective strengths in R&D, innovation, and market channels to achieve mutual benefits and win-win outcomes, with the aim of introducing more high-quality, high-level innovative products to the healthcare market.

Yu Zhihua, Founding Partner of Lapam CapitalStatement: Yingshu Life possesses fully independent R&D capabilities and the ability to innovatively upgrade core endoscopic components, thereby resolving critical technological bottlenecks. This core competency is scarce within the niche industry and provides the company with a competitive advantage for future development. The endoscopy sector is a mature clinical application area with a large market scale within the medical equipment and devices industry. Given that imported products still dominate the market and products are in an upgrade cycle, Yingshu Life is expected to expand its market presence and achieve continuous growth by leveraging its breakthroughs in bottleneck technologies, cost advantages derived from innovative optimization, and innovative products that offer significant health economic benefits aligned with clinical needs.

Yingshu Life is a medical device company engaged in the research, development, manufacturing, and sales of high-end medical endoscopy systems and related innovative products. The company’s product portfolio includes minimally invasive rigid endoscopy systems, optical rigid endoscopes, single-use electronic endoscopes, and high-value consumables associated with endoscopic procedures. Its solutions serve multiple clinical departments, including general surgery, urology, gynecology, and pulmonology. Currently, the company has established operations in Shenzhen, Hunan, and Hangzhou, featuring over 3,000 square meters of GMP-compliant sterile manufacturing facilities.

Weigao Songyuan Fund was established in December 2020 with a size of RMB 2 billion, initiated and led by Weigao Group. The fund focuses on investment targets related to innovative medical devices, biopharmaceuticals, healthcare services, and rehabilitation and elderly care. Leveraging Weigao Group’s extensive experience and industrial advantages in the healthcare sector, the fund helps its portfolio companies achieve rapid growth. Meanwhile, Weigao Group will utilize this fund to accelerate its strategic layout in high-quality upstream and downstream targets within its industrial chain, as well as in emerging areas of healthcare.

Headquartered in Beijing, Lapam Capital is a leading venture capital firm specializing in the biopharmaceutical sector in China. Currently, Lapam Capital manages five RMB-denominated funds and one USD-denominated fund, with total assets under management exceeding RMB 10 billion. It is the only biopharmaceutical investment institution to have received capital commitments from both of China’s top two RMB limited partners (LPs)—the National Council for Social Security Fund and the National Small and Medium Enterprises Development Fund.Lapam Capital focuses on investments in innovative drugs and innovative medical devices, primarily targeting early-stage, start-up, and growth-stage companies. To date, it has invested in over 120 companies, including more than 100 innovative drug enterprises and over 20 innovative medical device companies. Its portfolio features numerous standout projects such as Beta Pharma (SZ.300558), RemeGen (SH.688331), Yihua Pharmaceutical (SH.688176), Kaiyin Technology (SH.688687), ImmuneOnco (HK.01541), Aier Eye Hospital Group’s subsidiary Aibo Medical (SH.688050), Contineum Pharmaceuticals (GYRE), Huahao Zhongtian, BinHui Biotech, and Wuhe Bo’ao.Many partners within Lapam Capital’s management team possess over 20 years of international and domestic experience in biopharmaceutical R&D and management, enabling the firm to provide comprehensive value-added services to its portfolio companies.